Aim is to move above 20% EBITDA, says GSK Pharma
  • 5 years ago
From the Motilal Oswal 15th Investor Conference, Annaswamy Vaidheesh, vice president P-South Asia and India MD of Glaxosmithkline Pharmaceuticals shared his views and outlook.
Recommended